Challenges for Immunotherapy in Multiple Myeloma: Bone Marrow Microenvironment-Mediated Immune Suppression and Immune Resistance
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Challenges for Immunotherapy in Multiple Myeloma: Bone Marrow Microenvironment-Mediated Immune Suppression and Immune Resistance
Authors
Keywords
-
Journal
Cancers
Volume 12, Issue 4, Pages 988
Publisher
MDPI AG
Online
2020-04-21
DOI
10.3390/cancers12040988
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- The Impact and Modulation of Microenvironment-Induced Immune Resistance Against CAR T Cell and Antibody Treatments in Multiple Myeloma
- (2020) Lisa C. Holthof et al. BLOOD
- Re-establishing Apoptosis Competence in Bone Associated Cancers via Communicative Reprogramming Induced Through Notch Signaling Inhibition
- (2019) Michela Colombo et al. Frontiers in Pharmacology
- Evaluation of regulatory T cells (Tregs) alterations in patients with multiple myeloma treated with bortezomib or lenalidomide plus dexamethasone: correlations with treatment outcome
- (2019) Christina Hadjiaggelidou et al. ANNALS OF HEMATOLOGY
- Combined CD28 and 4-1BB Costimulation Potentiates Affinity-tuned Chimeric Antigen Receptor–engineered T Cells
- (2019) Esther Drent et al. CLINICAL CANCER RESEARCH
- Preclinical evidence for an effective therapeutic activity of FL118, a novel survivin inhibitor, in patients with relapsed/refractory multiple myeloma
- (2019) Lisa C. Holthof et al. HAEMATOLOGICA
- Transforming Growth Factor-β Signaling in Immunity and Cancer
- (2019) Eduard Batlle et al. IMMUNITY
- Emerging Role of Mesenchymal Stromal Cell-Derived Extracellular Vesicles in Pathogenesis of Haematological Malignancies
- (2019) Juçara Gastaldi Cominal et al. Stem Cells International
- The future of checkpoint inhibition in multiple myeloma?
- (2019) Caitlin Costello Lancet Haematology
- Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial
- (2019) Maria-Victoria Mateos et al. Lancet Haematology
- Pembrolizumab plus lenalidomide and dexamethasone for patients with treatment-naive multiple myeloma (KEYNOTE-185): a randomised, open-label, phase 3 trial
- (2019) Saad Zafar Usmani et al. Lancet Haematology
- Efficient apoptosis requires feedback amplification of upstream apoptotic signals by effector caspase-3 or -7
- (2019) Scott McComb et al. Science Advances
- Translating gammadelta (γδ) T cells and their receptors into cancer cell therapies
- (2019) Zsolt Sebestyen et al. NATURE REVIEWS DRUG DISCOVERY
- TLR4 signaling drives mesenchymal stromal cells commitment to promote tumor microenvironment transformation in multiple myeloma
- (2019) Cesarina Giallongo et al. Cell Death & Disease
- Ectopic expression of BIRC5-targeting miR-101-3p overcomes bone marrow stroma-mediated drug resistance in multiple myeloma cells
- (2019) Jahangir Abdi et al. BMC CANCER
- Multiple myeloma exploits Jagged1 and Jagged2 to promote intrinsic and bone marrow-dependent drug resistance
- (2019) Michela Colombo et al. HAEMATOLOGICA
- Recent updates on CAR T clinical trials for multiple myeloma
- (2019) Quande Lin et al. Molecular Cancer
- TIGIT as an emerging immune checkpoint
- (2019) H. Harjunpää et al. CLINICAL AND EXPERIMENTAL IMMUNOLOGY
- FL118 inhibits viability and induces apoptosis of colorectal cancer cells via inactivating the CIP2A/PP2A axis
- (2019) Xuezhu Lin et al. LIFE SCIENCES
- CAR T-cell therapy: is it prime time in myeloma?
- (2019) Surbhi Sidana et al. Hematology-American Society of Hematology Education Program
- Chimeric Antigen Receptor T-Cell Therapy for Multiple Myeloma
- (2019) Naoki Hosen Cancers
- TIGIT immune checkpoint blockade restores CD8+T cell immunity against multiple myeloma
- (2018) Camille Guillerey et al. BLOOD
- Antigen-specific primed cytotoxic T cells eliminate tumour cells in vivo and prevent tumour development, regardless of the presence of anti-apoptotic mutations conferring drug resistance
- (2018) Paula Jaime-Sánchez et al. CELL DEATH AND DIFFERENTIATION
- CD38-targeting antibodies in multiple myeloma: mechanisms of action and clinical experience
- (2018) Kristine A. Frerichs et al. Expert Review of Clinical Immunology
- Blocking IFNAR1 inhibits multiple myeloma–driven Treg expansion and immunosuppression
- (2018) Yawara Kawano et al. JOURNAL OF CLINICAL INVESTIGATION
- CD38-mediated immunosuppression as a mechanism of tumor cell escape from PD-1/PD-L1 blockade
- (2018) Limo Chen et al. Cancer Discovery
- APRIL signaling via TACI mediates immunosuppression by T regulatory cells in multiple myeloma: therapeutic implications
- (2018) Yu-Tzu Tai et al. LEUKEMIA
- Targeting B Cell Maturation Antigen (BCMA) in Multiple Myeloma: Potential Uses of BCMA-Based Immunotherapy
- (2018) Shih-Feng Cho et al. Frontiers in Immunology
- Increased activated regulatory T cell subsets and aging Treg-like cells in multiple myeloma and monoclonal gammopathy of undetermined significance: a case control study
- (2018) Ji-nuo Wang et al. Cancer Cell International
- Osteoclasts promote immune suppressive microenvironment in multiple myeloma: therapeutic implication
- (2016) G. An et al. BLOOD
- APRIL and BCMA promote human multiple myeloma growth and immunosuppression in the bone marrow microenvironment
- (2016) Y.-T. Tai et al. BLOOD
- Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma
- (2016) J. Krejcik et al. BLOOD
- IL-6 down-regulates HLA class II expression and IL-12 production of human dendritic cells to impair activation of antigen-specific CD4+ T cells
- (2016) Yosuke Ohno et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Sepantronium bromide (YM155) improves daratumumab-mediated cellular lysis of multiple myeloma cells by abrogation of bone marrow stromal cell-induced resistance
- (2016) S. J. de Haart et al. HAEMATOLOGICA
- Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib Study
- (2016) Alexander M. Lesokhin et al. JOURNAL OF CLINICAL ONCOLOGY
- Microenvironment drug resistance in multiple myeloma: emerging new players
- (2016) Lucia Di Marzo et al. Oncotarget
- Sepantronium bromide (YM155) improves daratumumab-mediated cellular lysis of multiple myeloma cells by abrogation of bone marrow stromal cell-induced resistance
- (2016) S. J. de Haart et al. HAEMATOLOGICA
- Pathogenesis beyond the cancer clone(s) in multiple myeloma
- (2015) G. Bianchi et al. BLOOD
- The impact of circulating suppressor cells in multiple myeloma patients on clinical outcome of DLIs
- (2015) L E Franssen et al. BONE MARROW TRANSPLANTATION
- Immunoregulatory Effects of Mesenchymal Stem Cell-Derived Extracellular Vesicles on T Lymphocytes
- (2015) Andrea Del Fattore et al. CELL TRANSPLANTATION
- Lenalidomide Enhances Immune Checkpoint Blockade-Induced Immune Response in Multiple Myeloma
- (2015) G. Gorgun et al. CLINICAL CANCER RESEARCH
- Mouse Cytotoxic T Cell-derived Granzyme B Activates the Mitochondrial Cell Death Pathway in a Bim-dependent Fashion
- (2015) Elena Catalán et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Stromal cell-mediated mitochondrial redox adaptation regulates drug resistance in childhood acute lymphoblastic leukemia
- (2015) Jizhong Liu et al. Oncotarget
- Granzyme A activates another way to die
- (2015) Judy Lieberman IMMUNOLOGICAL REVIEWS
- Understanding biology to tackle the disease: Multiple myeloma from bench to bedside, and back
- (2014) Giada Bianchi et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Apo2L/TRAIL and the Death Receptor 5 Agonist Antibody AMG 655 Cooperate to Promote Receptor Clustering and Antitumor Activity
- (2014) Jonathan D. Graves et al. CANCER CELL
- Immune impairments in multiple myeloma bone marrow mesenchymal stromal cells
- (2014) Thibaud André et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- FL118 Induces p53-Dependent Senescence in Colorectal Cancer Cells by Promoting Degradation of MdmX
- (2014) X. Ling et al. CANCER RESEARCH
- Preclinical Evidence for the Therapeutic Potential of CD38-Targeted Immuno-Chemotherapy in Multiple Myeloma Patients Refractory to Lenalidomide and Bortezomib
- (2014) I. S. Nijhof et al. CLINICAL CANCER RESEARCH
- Daratumumab-mediated lysis of primary multiple myeloma cells is enhanced in combination with the human anti-KIR antibody IPH2102 and lenalidomide
- (2014) I. S. Nijhof et al. HAEMATOLOGICA
- Bone Marrow Stroma Confers Resistance to Apo2 Ligand/TRAIL in Multiple Myeloma in Part by Regulating c-FLIP
- (2014) L. E. Perez et al. JOURNAL OF IMMUNOLOGY
- Tumor-promoting immune-suppressive myeloid-derived suppressor cells in the multiple myeloma microenvironment in humans
- (2013) G. T. Gorgun et al. BLOOD
- Accessory Cells of the Microenvironment Protect Multiple Myeloma from T-Cell Cytotoxicity through Cell Adhesion-Mediated Immune Resistance
- (2013) S. J. de Haart et al. CLINICAL CANCER RESEARCH
- Myeloid-Derived Suppressor Cells Regulate Growth of Multiple Myeloma by Inhibiting T Cells in Bone Marrow
- (2013) I. R. Ramachandran et al. JOURNAL OF IMMUNOLOGY
- Compartment-specific bioluminescence imaging platform for the high-throughput evaluation of antitumor immune function
- (2012) D. W. McMillin et al. BLOOD
- Reconstructing the human hematopoietic niche in immunodeficient mice: opportunities for studying primary multiple myeloma
- (2012) R. W. J. Groen et al. BLOOD
- The Role of Regulatory T Cells and TH17 Cells in Multiple Myeloma
- (2012) Walter M. T. Braga et al. Clinical & Developmental Immunology
- Anti-IL-6 receptor mAb eliminates myeloid-derived suppressor cells and inhibits tumor growth by enhancing T-cell responses
- (2012) Kentaro Sumida et al. EUROPEAN JOURNAL OF IMMUNOLOGY
- Marrow stromal cells induce B7-H1 expression on myeloma cells, generating aggressive characteristics in multiple myeloma
- (2012) H Tamura et al. LEUKEMIA
- A Novel Small Molecule FL118 That Selectively Inhibits Survivin, Mcl-1, XIAP and cIAP2 in a p53-Independent Manner, Shows Superior Antitumor Activity
- (2012) Xiang Ling et al. PLoS One
- Notch-1 signaling facilitates survivin expression in human non-small cell lung cancer cells
- (2011) Yuqing Chen et al. CANCER BIOLOGY & THERAPY
- A quarter century of granzymes
- (2011) C L Ewen et al. CELL DEATH AND DIFFERENTIATION
- Drozitumab, a Human Antibody to Death Receptor 5, Has Potent Antitumor Activity against Rhabdomyosarcoma with the Expression of Caspase-8 Predictive of Response
- (2011) Z. Kang et al. CLINICAL CANCER RESEARCH
- Survivin upregulation, dependent on leptin-EGFR-Notch1 axis, is essential for leptin-induced migration of breast carcinoma cells
- (2011) B. B. Knight et al. ENDOCRINE-RELATED CANCER
- Roles of the Ras/Raf/MEK/ERK pathway in leukemia therapy
- (2011) L S Steelman et al. LEUKEMIA
- Multiple Myeloma
- (2011) Antonio Palumbo et al. NEW ENGLAND JOURNAL OF MEDICINE
- IGF-1 suppresses Bim expression in multiple myeloma via epigenetic and posttranslational mechanisms
- (2010) E. De Bruyne et al. BLOOD
- Reconstitution of PTEN activity by CK2 inhibitors and interference with the PI3-K/Akt cascade counteract the antiapoptotic effect of human stromal cells in chronic lymphocytic leukemia
- (2010) M. Shehata et al. BLOOD
- The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody
- (2010) D. M. Benson et al. BLOOD
- Granzymes in cancer and immunity
- (2010) S P Cullen et al. CELL DEATH AND DIFFERENTIATION
- Towards effective immunotherapy of myeloma: enhanced elimination of myeloma cells by combination of lenalidomide with the human CD38 monoclonal antibody daratumumab
- (2010) M. S. van der Veer et al. HAEMATOLOGICA
- Survivin is upregulated in myeloma cell lines cocultured with mesenchymal stem cells
- (2010) Xiaofang Wang et al. LEUKEMIA RESEARCH
- Tumor cell-specific bioluminescence platform to identify stroma-induced changes to anticancer drug activity
- (2010) Douglas W McMillin et al. NATURE MEDICINE
- Knockdown of the interleukin-6 receptor alpha chain of dendritic cell vaccines enhances the therapeutic potential against IL-6 producing tumors
- (2010) Wonchan Hwang et al. VACCINE
- Bortezomib restores stroma-mediated APO2L/TRAIL apoptosis resistance in multiple myeloma
- (2009) Lia E. Perez et al. EUROPEAN JOURNAL OF HAEMATOLOGY
- Environmental-mediated drug resistance: a target for multiple myeloma therapy
- (2009) Kenneth H Shain et al. Expert Review of Hematology
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started